Dr. Nader Sanai presents the findings of a phase 0/1 trigger trial (NCT06072586) that evaluates the CNS penetration of BDTX-1535 in patients with recurrent high-grade gliomas and EGFR mutations.
Video Player is loading.
Play Video
Play
Mute
Current Time
/
Duration
Loaded: 0%
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -
1x
Playback Rate
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
Chapters
Descriptions
descriptions off, selected
Captions
captions and subtitles off, selected
Audio Track
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Reset restore all settings to the default valuesDone